Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP-258 for Treatment of Idiopathic Hypersomnia: Randomized Withdrawal Phase 3 Study
2018-001311-79Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypersomnolence disorder comparing JZP-258 continued treatment arm with Placebo withdrawal arm (2 arms). Primary endpoint: Change in Epworth Sleepiness Scale from end of stable dose period. Started Oct 2018; status: completed.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on 2018-001311-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001311-79.